Differences in verapamil response between CYP3A5 genotypes.

被引：1
|
作者：
Langaee, TY
Yarandi, HN
Katz, DA
Dehoff, RM
Kehoe, JM
Klocman, AS
Pepine, CJ
Johnson, JA
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.043
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P12 / P12
页数：1
相关论文
共 50 条
  • [1] CYP3A5 genotypes and effect of verapamil on midazolam pharmacokinetics
    Wang, YH
    Jin, Y
    Hu, ZQ
    Ho, H
    Hamman, MA
    Gorski, JC
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 119 - 119
  • [2] Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil
    Langaee, T. Y.
    Gong, Y.
    Yarandi, H. N.
    Katz, D. A.
    Cooper-DeHoff, R. M.
    Pepine, C. J.
    Johnson, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) : 386 - 391
  • [3] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [4] Effect of CYP3A5 genotype on the extent of CYP3A inhibition by verapamil.
    Wang, Y
    Jin, Y
    Hilligoss, JK
    Ho, H
    Hamman, MA
    Hu, Z
    Gorski, JC
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P3 - P3
  • [5] Frequencies of CYP3A5 genotypes and haplotypes in a Korean population
    Park, S. Y.
    Kang, Y. S.
    Jeong, M. S.
    Yoon, H. K.
    Han, K. O.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (01) : 61 - 65
  • [6] Elevated oral clearance of verapamil in CYP3A5 expressers.
    Jin, Y
    Wang, Y
    Hamman, MA
    Marunde, R
    Hu, Z
    Hilligoss, J
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P40 - P40
  • [7] The association between CYP3A5 genotype and antihypertensive response.
    Ho, H
    Hall, SD
    Flockhart, DA
    Li, L
    Skaar, T
    Cadman, P
    O'Connor, DT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P62 - P62
  • [8] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil
    Wang, YH
    Jones, DR
    Hall, SD
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (05) : 664 - 671
  • [9] CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer
    Plummer, SJ
    Conti, DV
    Paris, PL
    Curran, AP
    Casey, G
    Witte, JS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (09) : 928 - 932
  • [10] Effect of CYP3A5, CYP3A5 and ABCB1 Genotypes in Tacrolimus Dose and Clinical Outcomes after Heart Transplantation
    Tavira, B.
    Diaz-Molina, B.
    Lambert, J. L.
    Bernardo, M. J.
    Moris, C.
    Alvarez, V.
    Lopez-Larrea, C.
    Coto, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S154 - S154
12345